SUBSCRIBE
SUBSCRIBE
News   Policy

NicOx SA Plans to Appeal U.S. Naproxcinod Refusal

February 24, 2011 | 
1 min read

PARIS, Feb 24 (Reuters) - French biotech NicOx (NCOX.PA) plans to appeal the decision of the U.S. health regulator to turn down its anti-inflammatory drug naproxcinod for marketing approval, the French biotech said on Thursday.

Regulatory Europe
MORE ON THIS TOPIC
The EMA's former headquarters in London
Europe
Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion
March 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Editorial
Transparency Missing in Action at HHS Despite Leaders’ Calls for Clarity
February 28, 2025
 · 
4 min read
 · 
Heather McKenzie
Pictured: Regeneron logo on a light brown building
Lymphoma
Regeneron Narrows Approval Aspirations for Lymphoma Bispecific, Citing ‘Competitor Developments’
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Pictured: A syringe broken in half with long hallway in background/Nicole Bean for BioSpace
Vaccines
Meeting of FDA’s Vaccines Advisory Panel Canceled as Kennedy Settles Into HHS
February 27, 2025
 · 
2 min read
 · 
Tristan Manalac